Kotra Industries BhdXKLS:0002 84 EBITDA Margin % is 27.44% as of Mar. 2026, which is 5% above its 10-year median of 26.16. GuruFocus rates XKLS:0002 with a GF Score™ of 84/100 and a GF Value™ of RM4.33 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 955 Drug Manufacturers companies, Kotra Industries Bhd ranks better than 82.62% on this metric.
Kotra Industries Bhd (XKLS:0002) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Kotra Industries Bhd EBITDA Margin % Related Terms
Kotra Industries Bhd EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Kotra Industries Bhd's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:0002 vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kotra Industries Bhd's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kotra Industries Bhd EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kotra Industries Bhd's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Kotra Industries Bhd's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kotra Industries Bhd (XKLS:0002) has a EBITDA Margin % of 27.44% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kotra Industries Bhd and its competitors. This is near median its historical median of 26.16. Over the past decade, Kotra Industries Bhd's EBITDA Margin % has ranged from 17.56 to 35.34. According to the industry distribution chart, Kotra Industries Bhd ranks #166 out of 955 companies in the Drug Manufacturers industry, placing it in the top 17.4%.
Is Kotra Industries Bhd's EBITDA Margin % too high?
Kotra Industries Bhd's current EBITDA Margin % of 27.44% is near median its 10-year median of 26.16. Over the past 10 years, this metric has ranged from a low of 17.56 to a high of 35.34. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Kotra Industries Bhd's value of 27.44% is 121.5% above this industry median. Based on the distribution chart, Kotra Industries Bhd ranks #166 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kotra Industries Bhd has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kotra Industries Bhd's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kotra Industries Bhd ranks #166 out of 955 companies for EBITDA Margin %. This places Kotra Industries Bhd in the top 17% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. Kotra Industries Bhd's value of 27.44% is 121.5% above this benchmark. Historically, Kotra Industries Bhd's own EBITDA Margin % has ranged from 17.56 to 35.34 over the past decade. While the company's 10-year median is 26.16 vs. the industry median of 12.39, Kotra Industries Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kotra Industries Bhd's current EBITDA Margin % of 27.44% is 121.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kotra Industries Bhd and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kotra Industries Bhd's current EBITDA Margin % is 27.44%, which is near median its own 10-year median of 26.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kotra Industries Bhd stock overvalued right now?
Based on GuruFocus' analysis, Kotra Industries Bhd (XKLS:0002) is currently considered Modestly Undervalued. The stock's GF Value™ is RM4.33, compared to a current price of RM3.71 — trading 14.3% below its estimated fair value. The current EBITDA Margin % is 27.44%, which is near median its 10-year median of 26.16 and 121.5% above the Drug Manufacturers industry median of 12.39. Kotra Industries Bhd's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Kotra Industries Bhd (XKLS:0002), the current EBITDA Margin % is 27.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kotra Industries Bhd (XKLS:0002) Overvalued in 2026?
Based on GuruFocus' analysis, Kotra Industries Bhd stock appears to be undervalued.
The current stock price of RM3.71 is trading 14.3% below its estimated GF Value™ of RM4.33.
GuruFocus considers Kotra Industries Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:0002:
EBITDA Margin %: 27.44% (near median its 10-year median of 26.16)
GF Value™: RM4.33 vs. price of RM3.71 (14.3% below fair value)
Industry Position: 121.5% above the Drug Manufacturers median (#166 of 955)
No single metric tells the full story. See the XKLS:0002 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kotra Industries Bhd is a Malaysian pharmaceutical company engaged in the development, manufacturing, and supply of pharmaceutical and healthcare products supporting all life stages. Its portfolio includes life-saving medicines, OTC supplements, and nutrition products. The Group markets three core brands: Appeton, offering health supplements and nutrition across all age groups; Vaxcel, providing injectable medicines for infectious diseases, kidney care, and gastroenterology; and Axcel, specializing in oral and topical medicines for paediatrics, dermatology, and infectious diseases. The company operates in Malaysia and overseas, with the majority of revenue derived from Malaysia.
84GF Score
Get the complete analysis for XKLS:0002
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0002 has been successfully added to your 
